Valuation: Ocugen, Inc.

Market Cap 443M 385M 359M 330M 624M 42.18B 631M 4.23B 1.65B 21.09B 1.67B 1.63B 69.87B P/E 2026 *
-5.87x
P/E 2027 * -5.4x
Enterprise Value 381M 331M 308M 283M 536M 36.24B 542M 3.64B 1.42B 18.11B 1.43B 1.4B 60.02B EV / Sales 2026 *
93x
EV / Sales 2027 * 39.1x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 week+1.10%
Current month+2.23%
1 month-16.94%
3 months-31.12%
6 months-7.81%
Current year-13.88%
1 week 1.03
Extreme 1.026
1.17
1 month 1.03
Extreme 1.026
1.34
3 years 0.33
Extreme 0.3264
2.35
5 years 0.33
Extreme 0.3264
15.88
Manager TitleAgeSince
Chief Executive Officer 62 27/09/2019
Director of Finance/CFO - 09/02/2026
Chief Operating Officer - 01/03/2026
Director TitleAgeSince
Chairman 62 27/09/2019
Director/Board Member 59 01/09/2013
Director/Board Member 59 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
+6.56%+1.10%+28.36%+116.06% 443M
-0.23%-3.51%-0.54%+13.14% 48B
+6.03%+5.22%+420.33%+519.87% 41.13B
-2.21%-6.07%+24.87%+5.20% 37.56B
+2.94%-2.25%+6.15%+59.69% 35.91B
+1.98%+4.74%+12.19%+41.37% 29.86B
+0.47%-3.87% - - 16.12B
+0.31%+0.72%+32.99%+122.25% 16.05B
+0.93%+1.22%+4.32%+18.32% 13.76B
-0.98%-12.98%-4.82%-38.09% 12.1B
Average +1.04%-1.81%+58.21%+95.31% 27.83B
Weighted average by Cap. +1.34%-0.93%+82.29%+116.65%

Financials

2026 *2027 *
Net sales 4.09M 3.56M 3.31M 3.05M 5.76M 389M 5.82M 39.08M 15.28M 195M 15.38M 15.04M 645M 11.35M 9.85M 9.19M 8.44M 15.96M 1.08B 16.14M 108M 42.34M 540M 42.62M 41.68M 1.79B
Net income -76.84M -66.72M -62.21M -57.15M -108M -7.31B -109M -733M -287M -3.65B -289M -282M -12.11B -85.3M -74.06M -69.05M -63.44M -120M -8.11B -121M -814M -318M -4.06B -320M -313M -13.44B
Net Debt -62.5M -54.27M -50.6M -46.48M -87.91M -5.95B -88.88M -597M -233M -2.97B -235M -230M -9.85B -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
-
Date Price Change
05/08/26 1.170 +6.56%
04/08/26 €1.098 +2.04%
03/08/26 €1.076 +0.19%
31/07/26 €1.074 -1.65%
30/07/26 €1.092 +5.20%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.310USD
Average target price
12.17USD
Spread / Average Target
+828.75%

Quarterly revenue - Rate of surprise